Pfizer reports positive results from Echelon-3 study
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Nadda expressed his concern about growing incidence of Non-Communicable Diseases and the importance of awareness regarding healthy diet and lifestyle
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Subscribe To Our Newsletter & Stay Updated